C105 improves cognition in MS patients

Cognition Pharmaceuticals says positive results from a Phase II trial of C105 (amphetamine sulfate) on 151 multiple sclerosis patients with documented cognitive dysfunction.

In the six-week placebo-controlled study, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the Brief Visuospatial Memory Test - Revised, total recall (p=0.041) and delayed recall (p<0.01), and the California Verbal Learning Test, Long Delay Free Recall (p=0.012). Safety data were unremarkable with a limited side effect profile, the firm noted, adding that C105 also demonstrated efficacy in improving memory function in patients with cognitive impairment secondary to MS.

At the 30mg peak dose, the active group exhibited statistically-significant improvement in performance on measures of both verbal and non-verbal delayed recall as well as improved memory retention.